Showing 21–30 of 75 results from Publika

McKie PM, Cataliotti A, Ichiki T, Sangaralingham SJ, Chen HH, Burnett JC (2014)
M-atrial natriuretic peptide and nitroglycerin in a canine model of experimental acute hypertensive heart failure: differential actions of 2 cGMP activating therapeutics
J Am Heart Assoc, 3 (1), e000206
PubMed 24385449 DOI 10.1161/JAHA.113.000206
Ichiki T, Izumi R, Cataliotti A, Larsen AM, Sandberg SM, Burnett JC (2013)
Endothelial permeability in vitro and in vivo: protective actions of ANP and omapatrilat in experimental atherosclerosis
Peptides, 48, 21-6
PubMed 23927843 DOI 10.1016/j.peptides.2013.07.020
Chen HH, Glockner JF, Schirger JA, Cataliotti A, Redfield MM, Burnett JC (2012)
Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide
J Am Coll Cardiol, 60 (22), 2305-12
PubMed 23122795 DOI 10.1016/j.jacc.2012.07.056
Macheret F, Heublein D, Costello-Boerrigter LC, Boerrigter G, McKie P, Bellavia D, Mangiafico S, Ikeda Y, Bailey K, Scott CG, Sandberg S, Chen HH, Malatino L, Redfield MM, Rodeheffer R, Burnett J, Cataliotti A (2012)
Human hypertension is characterized by a lack of activation of the antihypertensive cardiac hormones ANP and BNP
J Am Coll Cardiol, 60 (16), 1558-65
PubMed 23058313 DOI 10.1016/j.jacc.2012.05.049
Mangiafico S, Costello-Boerrigter LC, Andersen IA, Cataliotti A, Burnett JC (2012)
Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics
Eur Heart J, 34 (12), 886-893c
PubMed 22942338 DOI 10.1093/eurheartj/ehs262
Malatino LS, Cataliotti A, Stancanelli B, Zoccali C (2012)
Hepatocyte growth factor and cardiomyopathy in dialysis patients
Hypertension, 60 (3), e24; author reply e25-6
PubMed 22868387 DOI 10.1161/HYPERTENSIONAHA.112.198424
Cataliotti A, Costello-Boerrigter LC, Chen HH, Textor SC, Burnett JC (2012)
Sustained blood pressure-lowering actions of subcutaneous B-type natriuretic peptide (nesiritide) in a patient with uncontrolled hypertension
Mayo Clin Proc, 87 (4), 413-5
PubMed 22469356 DOI 10.1016/j.mayocp.2012.02.003
McKie PM, Cataliotti A, Sangaralingham SJ, Ichiki T, Cannone V, Bailey KR, Redfield MM, Rodeheffer RJ, Burnett JC (2011)
Predictive utility of atrial, N-terminal pro-atrial, and N-terminal pro-B-type natriuretic peptides for mortality and cardiovascular events in the general community: a 9-year follow-up study
Mayo Clin Proc, 86 (12), 1154-60
PubMed 22134933 DOI 10.4065/mcp.2011.0437
Martin FL, McKie PM, Cataliotti A, Sangaralingham SJ, Korinek J, Huntley BK, Oehler EA, Harders GE, Ichiki T, Mangiafico S, Nath KA, Redfield MM, Chen HH, Burnett JC (2011)
Experimental mild renal insufficiency mediates early cardiac apoptosis, fibrosis, and diastolic dysfunction: a kidney-heart connection
Am J Physiol Regul Integr Comp Physiol, 302 (2), R292-9
PubMed 22071162 DOI 10.1152/ajpregu.00194.2011
Sangaralingham SJ, Heublein DM, Grande JP, Cataliotti A, Rule AD, McKie PM, Martin FL, Burnett JC (2011)
Urinary C-type natriuretic peptide excretion: a potential novel biomarker for renal fibrosis during aging
Am J Physiol Renal Physiol, 301 (5), F943-52
PubMed 21865266 DOI 10.1152/ajprenal.00170.2011